



Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting

-Results from Interim Analysis of Phase 2b Trial of Oral VT-1161 in Onychomycosis Suggest Significant Advantages Over Current Therapies-

RESEARCH TRIANGLE PARK, N.C., July 13, 2016 – [Viamet Pharmaceuticals, Inc.](#) today announced that data from a planned interim analysis of RENOVATE, a Phase 2b clinical trial of VT-1161 in onychomycosis of the toenail, will be presented at the American Podiatric Medical Association 2016 Annual Meeting, to be held July 14-17, in Philadelphia. VT-1161, the company's lead product candidate, is a highly potent and selective orally-administered inhibitor of fungal CYP51.

Amir Tavakkol, Ph.D., Viamet's Chief Development Officer, will present a poster titled "A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Four Oral Dosing Regimens of VT-1161 in the Treatment of Patients with Moderate-Severe Toenail Onychomycosis: Results of a Planned Week 24 Interim Analysis", summarizing key efficacy and safety data from the interim analysis. Dr. Tavakkol will be available to address questions regarding the RENOVATE interim results on Saturday, July 16, from 12:30-2:30 p.m. (EST) in the conference Exhibit Hall.

"There is a tremendous need for new therapies for the treatment of onychomycosis," stated Dr. Tavakkol. "Onychomycosis affects approximately 32 million people in the United States and current therapies are suboptimal with respect to efficacy, safety and dosing convenience. Given the positive interim RENOVATE results and favorable safety profile demonstrated in previous clinical studies, we believe that VT-1161 has the potential to be a highly differentiated and effective new treatment for this infectious disease. We look forward to receiving the final results from the RENOVATE study during the fourth quarter of 2016."

About VT-1161

VT-1161 is a potent and selective orally-administered inhibitor of fungal CYP51 currently in Phase 2b clinical trials for the treatment of onychomycosis (the RENOVATE study) and recurrent vulvovaginal candidiasis (the REVIVE study). VT-1161 blocks the production of ergosterol, an essential component of the fungal cell membrane. In preclinical studies, VT-1161 has demonstrated broad-spectrum activity against both dermatophyte and yeast fungal pathogens, including those species that cause onychomycosis and recurrent vulvovaginal candidiasis. Given the clinical and pre-clinical profile of VT-1161, Viamet believes that it may minimize the safety liabilities that limit the use of current oral antifungal therapies, such as liver toxicity and drug-drug interactions. Viamet previously reported robust antifungal activity of VT-1161 in the interim results of the REVIVE study and a very favorable safety profile in a Phase 2a proof-of-concept study in the treatment of *tinea pedis*, or athlete's foot.

About the RENOVATE Study

RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation) is a randomized, double-blind, placebo-controlled, Phase 2b clinical trial of VT-1161 in patients with distal lateral subungual onychomycosis (DLSO) of the large toenail. The trial is evaluating two dose levels of VT-1161 administered once weekly for either 10 or 22 weeks following an initial two-week daily loading dose period. The trial has enrolled approximately 260 patients with 25-75% involvement of the large toenail at baseline at 32 sites throughout the United States. During the trial, patients will be followed for 60 weeks. The primary efficacy endpoint is complete cure of the target toenail at week 48, a composite endpoint that requires both complete clinical cure and negative mycology.



About Onychomycosis

Onychomycosis, a fungal infection that primarily involves the nail bed and surrounding tissues, is a common infection, affecting approximately 32 million individuals in the United States. The infection is characterized by deformation, discoloration, thickening and splitting of the nail, as well as separation of the nail plate from the nail bed. Damage to the nail can also result in pain when walking, limiting ambulation. The unsightly appearance of the infected nail and the perception that there is an active and contagious infection is a significant concern for many patients. Onychomycosis can also be a significant medical issue for diabetics or other patients with compromised immune systems or poor circulation of the lower extremities. In these patients, the infected nail can serve as an entry point for bacterial infection, which can in turn lead to serious complications such as tissue necrosis and amputation.

About Viamet (www.viamet.com)

Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs.

Media Contact:

Blair McCarthy Atkinson
MacDougal Biomedical Communications
Direct: +1 812 454 6257
Main: +1 781 235 3060
batkinson@macbiocom.com

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies are based in the Research Triangle Park region of North Carolina, USA.

###